All Comments by Paul Coleman
- The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.
- Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.
- Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
- Principal component analysis of FDG PET in amnestic MCI.
- Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
- Widespread changes in dendritic spines in a model of Alzheimer's disease.
- Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
- Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium.
- Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.
- Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.
- Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease.
- Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.
- Biomarkers for early detection of Alzheimer pathology.
- In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.
- Brain tissue microarrays in neurodegenerative diseases: validation of methodology and immunohistochemical study of growth-associated protein-43 and calretinin.